Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act

H.R. 4553 · 116th Congress · Sep 27, 2019 · Lineage

A BILL

To expand the tropical disease product priority review voucher program to encourage treatments for the Middle East respiratory syndrome, Nipah, and Rift Valley fever.

1. Short title

This Act may be cited as the “Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act”.

2. Expanding tropical disease product priority review voucher program to encourage treatments for Middle East respiratory syndrome, Nipah, and Rift Valley fever

Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended—

(1)

by redesignating subparagraph (S) as subparagraph (V); and

(2)

by inserting after subparagraph (R) the following:

“(S) Middle East respiratory syndrome.

“(T) Nipah.

“(U) Rift Valley fever.”

Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act

1. Short title

2. Expanding tropical disease product priority review voucher program to encourage treatments for Middle East respiratory syndrome, Nipah, and Rift Valley fever

Cite this provision

Incoming references